Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction

Launched by NOVARTIS PHARMACEUTICALS · Jun 8, 2015

Keywords

ClinConnect Summary

The study consisted of two parts: the core part and the Open label extension (OLE) epoch.

The core part of this study was a multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. and enalapril 10 mg b.i.d. on CV mortality and morbidity reduction in Japanese HF patients with reduced ejection fraction. Patients who met the eligibility criteria at screening entered a 2 week, single-blind, active treatment run-in epoch in which they received LCZ696 50 mg b.i.d. Patients who tolerated LCZ696 5...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent must be obtained before any assessment is performed.
• * Outpatients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction:
• • LVEF ≤ 35% at Visit 1 (any local measurement, made within the past 6 months using echocardiography, MUGA, CT scanning, MRI or ventricular angiography is also acceptable, provided no subsequent measurement above 35%)
• • NT-proBNP ≥ 600 pg/ml at Visit 1 OR NT-proBNP ≥ 400 pg/ml at Visit 1 and a hospitalization for HF within the last 12 months (according to central laboratory measurements)
• • Patients must be on an ACEI or an ARB at a stable dose for at least 4 weeks before Visit 1.
• • Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to Visit 1 (reason should be documented if patients reported contraindications or intolerance).
• • An aldosterone antagonist should also be considered in all patients, taking account of renal function, serum potassium and tolerability. If given, the dose of aldosterone antagonist should be optimized according to guideline recommendations and patient tolerability, and should be stable for at least 4 weeks prior to Visit 1. Other evidence-based therapy for HF should also be considered e.g. cardiac resynchronization therapy and an implantable cardioverter-defibrillator in selected patients, as recommended by guidelines.
• Exclusion Criteria:
• • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes, ACEIs, ARBs, NEP inhibitors as well as known or suspected contraindications to the study drugs.
• • Previous documented history of intolerance to ACEIs or ARBs.
• • Known history of angioedema.
• • Requirement of treatment with both ACEIs and ARBs.
• • Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy).
• • Symptomatic hypotension and/or a SBP \< 100 mmHg at screening or \< 95 mmHg at the end of run-in.
• • Estimated GFR \< 30 mL/min/1.73 m2 as measured by the Japanese formula at screening, or the end of run-in or \> 35% decline in eGFR between screening and end of run-in (according to local measurements).
• • Serum potassium \> 5.2 mmol/L (mEq/L) at screening or \> 5.4 mmol/L (mEq/L) at the end of run-in (according to local measurements).
• • Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty within the 3 months prior to Visit 1.
• • Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months prior to Visit 1.
• • Symptomatic bradycardia or second (except asymptomatic Wenckebach block) or third degree heart block without a pacemaker.
• • Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation.
• • Presence of other hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis.
• • Presence of bilateral renal artery stenosis.